Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
José Claudio Casali da Rocha
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07167329CT.gov Real-World Effectiveness and Pharmacogenetics of Belzutifan in VHL Syndrome: The BELIEVE-VHL Trial | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Primitive Neuroectodermal Tumor
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Belzutifan (this asset) | José Claudio Casali da Rocha | P2 | CCC · 53 |
| Tasadenoturev | DNAtrix, Inc. | P2 | B |
| Cixutumumab | National Cancer Institute (NCI) | P2 | B |
| Pembrolizumab | DNAtrix, Inc. | P2 | B |
| Genistein | University of Virginia | P2 | CCC |
| Nivolumab | Instituto do Cancer do Estado de São Paulo | P2 | CCC |
| Nivestim | St. Jude Children's Research Hospital | P1 | CCC |
| Pralsetinib, Trans- | Hoffmann-La Roche | P1/2 | CCC |
| Interleukin-12 | Second Affiliated Hospital, School of Medicine, Zhejiang University | P1/2 | CCC |
+13 more in the Primitive Neuroectodermal Tumor cohort
Other indications for Belzutifan
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Renal Cell Carcinoma | — | P3 | BBB · 73 |
| Von Hippel-Lindau Disease | — | P3 | BB · 64 |
| Clear Cell Renal Carcinoma | — | P2 | B · 60 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Belzutifan in Primitive Neuroectodermal Tumor. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/belzutifan-primitive-neuroectodermal-tumor
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →